Viewing nowLiriel Orally Disintegrating Tablet 75 mg (Pregabalin)
Pregabalin 75mg
Orally disintegrating Tablet · Prescription medication
GL Pharma Co., Ltd.

MFDS item code 202600402 · Approved 2026.02.12
Treatment of neuropathic pain, adjunctive treatment of partial-onset epileptic seizures, and treatment of fibromyalgia
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for the treatment of partial seizures in adults with epilepsy. Additionally, it is effective in treating fibromyalgia. In summary, this drug is used for the treatment of neuropathic pain, partial seizures in epilepsy, and fibromyalgia.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Place the tablet on the tongue and swallow it without water once it has disintegrated. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Because the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: A supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior, so if there are abnormal changes in mood or behavior while taking it, you should immediately inform your healthcare provider. Patients with hypersensitivity to this medication should not take it. Diabetic patients may experience weight gain when taking this medication, so adjustments to their blood sugar control medications may be necessary. If allergic reactions such as angioedema occur, use should be immediately discontinued. Elderly patients should be cautious, as dizziness and drowsiness may occur when taking this medication; should such symptoms arise, there is a risk of falls and other accidents. While taking this medication, visual disturbances or changes in vision may occur, and these symptoms may improve upon discontinuation of the drug. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so dosage adjustments should be made in consultation with a healthcare professional. Patients with a history of substance abuse may be at higher risk for misuse of this medication, and caution should be exercised while taking it. Patients with decreased kidney function may need dosage adjustments for this medication. Patients with heart disease should be cautious, as symptoms such as congestive heart failure may appear while taking this medication. The concomitant use of this medication with opioid analgesics can enhance central nervous system depression effects, leading to a risk of respiratory depression, so caution is advised. This medication can cause dizziness and drowsiness, so driving or operating hazardous machinery should be avoided until symptoms resolve. In early pregnancy, there is a risk of fetal malformation; therefore, women who are pregnant or planning to become pregnant should consult a doctor before taking this medication and should use effective contraception. Breastfeeding women are recommended to stop breastfeeding, as this medication can be transferred to breast milk, and the effects on infants are not fully known. In cases of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, and immediate medical attention should be sought for appropriate treatment. Keep out of reach of children, and transferring to other containers may pose risks of accidents or degradation of quality. If severe skin rashes, swelling, or difficulty breathing occur during use of this medication, discontinue use immediately and consult a healthcare provider.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, depression, uplifted mood, decreased libido, insomnia, depersonalization, disturbance of sexual sensation, restlessness, anxiety, mood swings, emotional decline, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, dizziness, drowsiness, ataxia, abnormal coordination, balance disorders, amnesia, attention deficit, memory impairment, tremors, speech disorders, sensory disturbances, sensory deficits, sedation, somnolence, cognitive impairment, nystagmus, language disorders, myoclonic jerks, reduced reflexes, motor abnormalities, psychomotor agitation, position-related dizziness, hypersensitivity, burning sensation, activity tremors, syncope, confusion, decreased physical activity, olfactory disturbances, loss of taste, writing disabilities, blurred vision, double vision, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, eye edema, decreased vision, ocular pain, eye fatigue, increased tear secretion, eye irritation, mydriasis, vibration-related changes in depth perception, strabismus, visual brightness, vertigo, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flush, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory reduction, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falling, feeling drunk, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, elevated serum creatine phosphokinase, increased aspartate aminotransferase, elevated blood glucose, decreased platelet count, decreased serum potassium, weight loss, elevated serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, loss of consciousness, mental disorders, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, glossitis, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, mood disorders, drowsiness, confusion state, depression, agitation, restlessness, seizures, mood disorders, drowsiness, confusion state, depression, agitation, restlessness, seizures
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to maintain storage temperature between 1 to 30 degrees Celsius (room temperature).
Light orange diamond-shaped orally disintegrating tablet
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Orally disintegrating Tablet · Prescription medication
GL Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.